Our Approach

Multi-Mechanistic Approach Maximinzing Therapeutic Effect

The Fusix approach is based on a proprietary best-in-class oncolytic virus platform that offers multiple therapeutic mechanisms to destroy the tumor. These include, but are not limited to the following aspects.

  1. Tumor-specific cell lysis through enhanced cell-cell fusion
  2. Release of therapeutic payload locally within the tumor
  3. Immune cell activation and priming of a systemic anti-tumor immune response that can find and attack additional tumor cells throughout the body
  4. Induction of local inflammation in the tumor, thereby enabling synergistic effects with other immunotherapeutic approaches

Fusion as a Differentiating Feature to Traditional Cancer Therapies

The Fusix technology relies on a unique, fusion-enhanced oncolytic virus platform. In this time-lapse video, FUSE-Basic destroys a monolayer of human liver cancer cells (HCC) within 48 hours through its potent, fusogenic mechanism of action. Infected cells fuse with surrounding tumor cells, creating a chain reaction in which a single infected tumor cell can lead to lysis of hundreds of tumor cells.

Fusion-Powered Immune Oncology

The InFUSE™ platform offers a unique mechanism of action that will revolutionize immune oncology in solid cancers. A complex interplay of cellular and molecular components make up the suppressive tumor microenvironment that fosters immune tolerance and renders many cancers refractory to standard immunotherapy approaches. The immune boosting effect induced by the InFUSE™ platform encompasses a cascade of events that not only directly destroy tumor cells but also foster a robust and sustained anti-tumor immune response, ultimately leading to tumor regression and potentially long-term protection against cancer recurrence.


Upon infecting cancer cells, the FUSE vectors undergo replication, leading to the fusion and subsequent lysis of infected cells. As the cancer cells die through this highly unusual mechanism of action, they trigger an inflammatory reaction, effectively “waking up” the immune system and alerting it to the presence of the tumor. This process represents an essential switch, that results in the priming and expansion of the key immune cells to actively target and eliminate the cancer. In addition to enhanced direct tumor cell killing effects, the FUSE vectors mediate a targeted immune cell attack against the cancer – all through the power of fusion. In addition, by converting immune-suppressed “cold” tumors into immune-stimulatory “hot” tumors patients are sensitized to all of the immunotherapy “tools” that are already on the market, through rationally designed combination approaches.